MicroRNA‑103 modulates tumor progression by targeting KLF7 in non‑small cell lung cancer
Affiliations: Department of Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China, Department of Anesthesiology, The Third People's Hospital of Yancheng, Yancheng, Jiangsu 224000, P.R. China
- Published online on: June 18, 2020 https://doi.org/10.3892/ijmm.2020.4649
Copyright: © Li
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Numerous studies have identified that microRNAs (miRs) play a crucial role in the tumorigenesis of non‑small cell lung cancer (NSCLC). However, to the best of our knowledge, the physiological function of miR‑103 in NSCLC is not fully understood. Experiments in the present study revealed that miR‑103 expression was increased in NSCLC cell lines. In addition, a series of methods, including MTT, colony formation, 5‑ethynyl‑2'‑deoxyuridine, Transwell, wound healing, flow cytometric, reverse transcription‑quantitative PCR and western blot assays, were performed, which revealed that overexpression of miR‑103 enhanced cell growth, migration, invasion and epithelial‑mesenchymal transition (EMT), and suppressed apoptosis of A549 and H1299 cells. Additionally, a dual‑luciferase reporter assay indicated that miR‑103 directly targets the 3'‑untranslated region of Kruppel‑like factor 7 (KLF7), and KLF7 expression was negatively regulated by miR‑103 expression. Furthermore, the present findings demonstrated that miR‑103 promoted EMT via regulating the Wnt/β‑catenin signaling pathway in NSCLC. Collectively, the current results demonstrated that miR‑103 serves a tumorigenesis role in NSCLC development by targeting KLF7, at least partly via the Wnt/β‑catenin signaling pathway. Consequently, these findings indicated that miR‑103/KLF7/Wnt/β‑catenin may provide a novel insight into underlying biomarkers for improving the diagnosis and treatment of NSCLC.